Biocon (BIOCON) | Stock Overview & Key Data
Biocon Performance Comparison
Stock Range
Today's Range
Low: ₹337.70
High: ₹350.30
on September 26, 2025
52 Week Range
Low: ₹291.00
High: ₹406.00
on March 3, 2025
on July 18, 2025
All-Time High: ₹487.75 on December 21, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR456.0B
EPS
3.20
P/E Ratio (TTM)
105.91
Forward P/E
34.16
P/B Ratio
1.88
PEG Ratio
-1.11
Div. Yield
0.26%
ROE
3.66%
Beta
0.234
Debt to Equity
66.26
Financial Highlights
Profitability
Gross Margin
64.06%
Operating Margin
7.46%
Profit Margin
2.44%
Returns and Earnings
Return on Assets (TTM)
1.72%
Return on Equity (TTM)
3.66%
EBITDA
INR24.3B
Net Income (TTM)
INR3.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR131.63
Quarterly Revenue Growth (YoY)
14.80%
Quarterly Earnings Growth (YoY)
-95.20%
Dividend Information
Last 12-Month Dividend
₹1.00
Current Dividend Yield
0.26%
3-Year Average Dividend Yield
0.36%
3-Year Average Annual Dividend
₹1.33
3-Year Total Dividends
₹4.00
Ex-Dividend Date
July 4, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Biocon BIOCON | 455.97B Large-cap | -3.38% | -1.11% | 1.29% | 2.24% | -3.48% | -3.50% | 22.34% | -21.36% |
| OneSource Specialty ONESOURCE | 207.35B Large-cap | -6.19% | -7.37% | -12.74% | 1.43% | 2.04% | 2.04% | 2.04% | 2.04% |
| Concord Biotech CONCORDBIO | 163.87B Mid-cap | -4.13% | -7.53% | -12.44% | -6.00% | -26.04% | -22.39% | 68.56% | 68.56% |
| Blue Jet Healthcare BLUEJET | 112.12B Mid-cap | -2.70% | -9.74% | -24.50% | -24.45% | 15.14% | 29.07% | 70.54% | 70.54% |
| Supriya Lifescience SUPRIYA | 59.72B Mid-cap | 7.61% | 11.94% | 10.49% | 1.97% | -2.01% | 31.41% | 147.06% | 53.26% |
| Dishman Carbogen DCAL | 44.90B Small-cap | 3.09% | 5.56% | 18.69% | 30.62% | 3.51% | 60.91% | 206.33% | 80.50% |
Ownership & Short Interest
Insider Ownership
56.07%
Institutional Ownership
24.15%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4M
Average 90-Day Volume
3M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BIOCON's 52-week high and low?
- In the last 52 weeks, Biocon reached a high of ₹406.00 (on July 18, 2025) and a low of ₹291.00 (on March 3, 2025).
- What is the market cap and P/E ratio for BIOCON?
- Curious about Biocon's size and valuation? Its market capitalization stands at 455.97B. When it comes to valuation, the P/E ratio (trailing twelve months) is 105.91, and the forward P/E (looking ahead) is 34.16.
- Does BIOCON pay dividends? If so, what's the yield?
- Yes, Biocon is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.26%, and the company has paid an average of ₹1.33 per share annually over the past 3 years.
- Who are Biocon's main competitors or similar companies to consider before investing?
When looking at Biocon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return OneSource Specialty
ONESOURCE207.35B Healthcare Biotechnology 2.04% 2.04% Concord Biotech
CONCORDBIO163.87B Healthcare Biotechnology -22.39% 68.56% Blue Jet Healthcare
BLUEJET112.12B Healthcare Biotechnology 29.07% 70.54% Supriya Lifescience
SUPRIYA59.72B Healthcare Biotechnology 31.41% 147.06% Dishman Carbogen
DCAL44.90B Healthcare Biotechnology 60.91% 206.33% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biocon Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Biocon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.66%, the Debt to Equity ratio from the most recent quarter is 66.26, and its Gross Profit Margin stands at 64.06%.
- What is the recent revenue and earnings growth for BIOCON?
- Looking at Biocon's growth, its revenue over the trailing twelve months (TTM) was INR158B. Compared to the same quarter last year (YoY), quarterly revenue grew by 14.80%, and quarterly earnings saw a YoY growth of -95.20%.
- How much of BIOCON stock is held by insiders and institutions?
- Wondering who owns Biocon stock? Company insiders (like executives and directors) hold about 56.07% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.15%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.